Mode
Text Size
Log in / Sign up
N/A N=1,647 Randomized Double-blind Prevention

An Innovative Conversational Agent (Quitbot) for Smoking Cessation

Smoking &Amp; Tobacco Cessation

Enrolled (actual)
1,647
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Number of Participants With 30-day Cigarette Smoking Cessation — 191; 186 Participants — p=0.720

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Experimental Smoking Cessation Program (Other); Control Smoking Cessation Program (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Fred Hutchinson Cancer Center
Primary completion
May 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With 30-day Cigarette Smoking Cessation
159; 153 0.525
SECONDARY
Number of Participants With 30-day Cigarette Smoking Cessation
159; 153 0.525

Summary

This phase III trial compares two remote digital smoking cessation programs to see how well they work for quitting smoking.

Eligibility Criteria

Inclusion Criteria

  • Age 18 or older
  • Smokes at least one cigarette a day for the past 12 months
  • Wants to quit cigarette smoking within the next 30 days (consistent with text messaging intervention trials)
  • If concurrently using any other nicotine or tobacco products, wants to quit using them within the next 30 days
  • Interested in learning skills to quit smoking
  • Willing to be randomly assigned to either intervention
  • Resides in United States (US) and will continue to reside in the US for the next 12 months
  • Has at least daily access to their own smartphone
  • Has text messaging on their smartphone and knows how to download a smartphone application
  • Willing and able to read in English, and
  • Not using other smoking cessation interventions (This eligibility requirement helps ensure results are due to the treatments we recommend rather than those that participants are doing on their own.)

Exclusion Criteria

  • The reverse of the inclusion criteria
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04308759). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search